Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Chlorproguanil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlorproguanil SCHEMBL44783 | 0.84 | EPHX1 (0.46) | PKMSMN1; SMN2MAPTALDH1A1LMNA | |
| Chlorproguanil SCHEMBL1000272 | 0.83 | SMN1; SMN2 (0.45) | PKMSMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL1983057 | 0.78 | EPHX1 (0.50) | PKMSMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL13584612 | 0.73 | EPHX1 (0.59) | PKMMAPTALDH1A1LMNAKDM4E | |
| SCHEMBL29518499 | 0.73 | EPHX1 (0.59) | PKMMAPTALDH1A1LMNAKDM4E | |
| Hydrochloric Acid SCHEMBL13584366 | 0.72 | EPHX1 (0.57) | PKMMAPTALDH1A1LMNAKDM4E | |
| SCHEMBL11815954 | 0.70 | SMN1; SMN2 (0.56) | PKMSMN1; SMN2MAPTALDH1A1LMNA | |
| Proguanil SCHEMBL45726 | 0.69 | LMNA (0.41) | PKMSMN1; SMN2MAPTALDH1A1LMNA | |
| SCHEMBL11644985 | 0.69 | NAMPT (0.51) | PKMCYP2C19SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL15102379 | 0.69 | CA1 (0.51) | SMN1; SMN2ALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-117597327-A | Pharmaceutical preparation | 第一波动生物制药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2022-01-06 | — | — | US | disclosed |
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FIRST WAVE BIO, INC. | 2021-12-30 | — | — | US | disclosed |
| US-20200276140-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-09-03 | — | — | US | disclosed |
| US-20200268694-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-08-27 | — | — | US | disclosed |
| US-10744103-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200197339-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200197340-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200147012-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | MONTERESEARCH S.R.L. (IT) | 2019-10-03 | — | — | US | disclosed |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2019-05-21 | — | — | US | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (19 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401784-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSE | FH, CS, ECHS1 | PKM 3195/4885CYP2C19 1305/4885PRMT1 4053/4885 |
| US-20200147012-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | PKM 3178/4885CYP2C19 1403/4885PRMT1 4052/4885 |
| US-20200197339-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | PKM 3177/4885CYP2C19 1409/4885PRMT1 4029/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | PKM 3178/4885CYP2C19 1403/4885PRMT1 4052/4885 |
| US-20200268694-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | PKM 3177/4885CYP2C19 1409/4885PRMT1 4029/4885 |
| US-10744103-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | PKM 3178/4885CYP2C19 1403/4885PRMT1 4052/4885 |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | PKM 3177/4885CYP2C19 1409/4885PRMT1 4029/4885 |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | ACE2, ACE, MME | PKM 3206/4885CYP2C19 12/4885PRMT1 1227/4885 |
| US-20200197340-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | PKM 3178/4885CYP2C19 1403/4885PRMT1 4052/4885 |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | PKM 3177/4885CYP2C19 1409/4885PRMT1 4029/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | PKM 3164/4885CYP2C19 12/4885PRMT1 1337/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | PKM 2923/4885CYP2C19 22/4885PRMT1 1533/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | PKM 2923/4885CYP2C19 22/4885PRMT1 1533/4885 |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | PKM 3177/4885CYP2C19 1409/4885PRMT1 4029/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | PKM 3269/4885CYP2C19 1410/4885PRMT1 3538/4885 |
| US-20220000812-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | PKM 3177/4885CYP2C19 1409/4885PRMT1 4029/4885 |
| US-20200147013-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | PKM 3177/4885CYP2C19 1409/4885PRMT1 4029/4885 |
| US-20200276140-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | PKM 3177/4885CYP2C19 1409/4885PRMT1 4029/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | PKM 3195/4885CYP2C19 1305/4885PRMT1 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.